Acarbose

# Acarbose ## Overview - **Classification**: Alpha-glucosidase inhibitor - **Mechanism**: Reversibly inhibits alpha-glucosidase enzymes in the small intestine. This delays digestion of complex carbohydrates, reducing postprandial glucose peaks. ## Primary Indications 1. **Type 2 Diabetes Mellitus**: As an adjunct to diet and exercise. 2. **Type 2 Diabetes Mellitus (Combination Therapy)**: Used with sulfonylureas, metformin, or insulin. ## Adult Dosing ### Standard Dosing **Type 2 Diabetes Mellitus** - **Dose**: Initiate with **25 mg** - **Frequency**: Three times daily (TID) - **Route**: Oral - **Timing**: Take with the first bite of each main meal. - **Titration**: Increase dose at 4-8 week intervals based on response/tolerability. - **Maintenance Dose**: **50 mg** to **100 mg** TID - **Maximum Dose**: **100 mg** TID for patients >60 kg body weight. - **Maximum Dose**: **50 mg** TID for patients ≤60 kg body weight. ### Dose Adjustments - **Renal Impairment**: **Contraindicated** if CrCl <25 mL/min. Not recommended if CrCl <30 mL/min. - **Hepatic Impairment**: No specific adjustment for mild-moderate. **Contraindicated** in severe hepatic impairment (e.g., cirrhosis). - **Elderly Patients**: Start with **25 mg** TID. Dose titration may be slower. Max dose **50 mg** TID if ≤60 kg. ## Pediatric Dosing *Acarbose is generally **not recommended** for pediatric patients. Safety and efficacy have not been established.* ### Neonates (0-28 days) - **Dose**: Not recommended. - **Special Notes**: Safety and efficacy not established. ### Infants (1-12 months) - **Dose**: Not recommended. - **Special Notes**: Safety and efficacy not established. ### Children (1-12 years) - **Dose**: Not recommended. - **Special Notes**: Safety and efficacy not established. ### Adolescents (13-18 years) - **Dose**: Not recommended. - **Special Notes**: Safety and efficacy not established. Clinical judgment may consider if adult criteria met, with careful monitoring. ## Safety Information ### Contraindications - **Absolute**: Diabetic ketoacidosis. - **Absolute**: Inflammatory bowel disease, colonic ulceration. - **Absolute**: Partial intestinal obstruction, predisposition to obstruction. - **Absolute**: Chronic intestinal diseases with marked digestion/absorption disorders. - **Absolute**: Conditions worsened by increased intestinal gas (e.g., large hernia). - **Absolute**: Severe renal impairment (CrCl <25-30 mL/min). - **Absolute**: Severe hepatic impairment (e.g., cirrhosis). - **Absolute**: Hypersensitivity to acarbose. - **Absolute**: Pregnancy and lactation. ### Common Adverse Effects - **Very Common (>10%)**: Flatulence (**77%**), abdominal pain (**21%**), diarrhea (**31%**). - **Common (1-10%)**: Elevated liver enzymes (transaminases), usually reversible. - **Serious but Rare**: Pneumatosis cystoides intestinalis. Severe hepatic injury (rare). Hypoglycemia (when used with insulin/sulfonylurea). ### Key Drug Interactions - **Intestinal Adsorbents (e.g., activated charcoal)**: May reduce acarbose effect; avoid concomitant use. - **Digestive Enzyme Preparations (e.g., amylase, pancreatin)**: May reduce acarbose effect; avoid concomitant use. - **Sulfonylureas/Insulin**: Increased risk of hypoglycemia. May need dose adjustment of sulfonylurea/insulin. Treat hypoglycemia with **glucose**, not sucrose. - **Digoxin**: Acarbose may reduce digoxin bioavailability. Monitor digoxin levels if co-administered. ## Monitoring & Follow-up - **Before Treatment**: Baseline HbA1c, serum creatinine, LFTs (ALT, AST). - **During Treatment**: HbA1c (every 3-6 months). Serum creatinine periodically. LFTs (ALT, AST) every 3 months during the first year, then periodically. - **Clinical Signs**: Monitor for persistent GI symptoms. Watch for signs of liver injury (jaundice, dark urine). Monitor for symptoms of hypoglycemia. ## Clinical Pearls - 💡 **Tip 1**: Always take acarbose with the **first bite of each main meal** for optimal efficacy. - 💡 **Tip 2**: Gastrointestinal side effects (flatulence, diarrhea) are very common, especially at initiation, but often decrease with continued use. - 💡 **Tip 3**: If hypoglycemia occurs (when used with insulin or sulfonylurea), treat with **pure glucose (dextrose)**. Acarbose blocks the breakdown of sucrose. - 💡 **Tip 4**: Slow dose titration over several weeks can help improve tolerability of GI side effects. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.